Amit Shah to inaugurate NCI on May 27

BHARATIYA Janata Party’s national President Amit Shah will inaugurate National Cancer Institute (NCI), a dream project of Maharashtra Chief Minister Devendra Fadnavis,on May27 .NCI is the 475-bed hospital run by Dr Aabaji That te Seva Aur Anusandhan Sanstha and will have state-of-theart facilities. The opening of the new cancer facility will bring affordable care for the needy of the region.
The institute, a green building, will comeupon8.78 lakh sq ft area. The project cost is being pegged at approximately Rs 250-275 crore. The new NCI medical facility will bring the much-needed relief to cancer patients of Central India. The other advantage of this new facility will be that treatment here would cost much less than similar services available at Tata Memorial Centre.
University recognised courses in the super-specialty in Oncology, Phd programmes, nurses and paramedical training will also be conducted by the NCI. Most cancer patient soft he region are diagnosed late and mostly in incurable stage. This is mainly because a wide gap exists in the options for cancer treatment in Central India.
Between Mumbai and Kolkata,there is no major cancerfacility. NCI will fill this gap.The trust is trying for a platinum rating and get recognised from Indian Green Building Council. Since many ailing patients cannot meet travelling,treatment and accommodation costs, an integrated palliative care centre was started at Dharampeth in 2012.This centre benefited 2,500 patients across Vidharba and Central India.
In an another development in NCI, legal luminary of the country former Advocate General of Maharashtra Senior Adv Sunil Manohar will become President of Dr Aabaji Thatte Seva Aur Anusandhan Sanstha that runs NCI.The post of President became vacant after Devendra Fadnavis became Chief Minister.
Theen tire project has been conceptualised and supervised by Secretary Shailesh Joglekar, Vice-President Ajay Sancheti and their devoted colleagues. Their efforts are getting equal support from Dr Anand Pathak, who is very respected Oncologist of the country. He is also the Medical Director of the NCI. Once NCI starts operating the people of this region need not go to other big cities for the treatment.
Source:http://thehitavada.com/Encyc/2017/5/8/Amit-Shah-to-inaugurate-NCI-on-May-27.aspx

Comments

Post a Comment

Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product ramucirumab (Cyramza). The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. The CHMP adopted a new indication as follows: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib”. For information, the full indications for Cyramza will be as follows : Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatm
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first three pillars. Fred
Read more

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types

Image
Bristol-Myers Squibb Company  (NYSE:BMY) and  Clovis Oncology, Inc. (Nasdaq:CLVS) announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb’s immunotherapy  Opdivo   and Clovis Oncology’s poly (ADP-ribose) polymerase (PARP) inhibitor  Rubraca  in pivotal phase 3 clinical trials in: Advanced ovarian cancer : First-line maintenance treatment study to evaluate  Rubraca  +  Opdivo ,  Rubraca ,  Opdivo  and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy. Advanced triple-negative breast cancers  (TNBC): First-line maintenance treatment study to evaluate  Rubraca  +  Opdivo ,  Rubraca ,  Opdivo  and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency (HRD). The collaboration will also include a Phase 2 study to e
Read more